Croatia estimated spending €42.07 million on GLP-1 drugs in 2024 [1]. That was 42.7% of its estimated spending on non-insulin diabetes drugs. GLP-1s accounted for 16.1% of standardized use in the same category.
How Croatia measured use and spending
The researchers counted use in defined daily doses and estimated spending using listed prices. GLP-1 use reached 15.99 daily doses per 1,000 residents in 2024. The whole drug category reached 99.36.
Published estimates cannot show what an insurer paid after discounts. The rules for US GLP-1 insurance coverage show how the reason for prescribing can affect payment. The Croatian totals do not isolate spending on weight management.
How many Australian adults met the criteria?
The Australian eligibility analysis explains how the authors applied treatment criteria to survey respondents. The estimates describe potential eligibility rather than the number of prescriptions filled.
Researchers applied approved prescribing criteria to Australian survey data from 2022 [2]. They estimated that 39.7% of adults met the criteria for long-term weight management, or about 7.8 million. Up to about 339,000 also met the cardiovascular criteria. These figures measure eligibility. They do not track prescriptions, public coverage or spending.
What happened to US medical spending?
A US household survey study estimated spending differences among adults with obesity [3]. Studies of whether GLP-1 drugs reduce healthcare spending separate pharmacy spending from other care. In this study, use was associated with $2,586 less in non-drug medical spending per person-year. Total medical spending was $6,483 higher after adjustment. The study cannot establish what caused the differences or what happens over several years.